Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758473 | 0.80 | SLC22A12 (0.56) | SLC22A12CYP11B1CYP11B2EGLN2CYP3A4 | |
| SCHEMBL6921694 | 0.79 | SLC22A12 (0.50) | SLC22A12RPS6KA3CYP11B1CYP11B2 | |
| SCHEMBL21397227 | 0.78 | SLC22A12 (0.54) | SLC22A12CYP11B1CYP11B2EGLN2CYP3A4 | |
| SCHEMBL6919942 | 0.78 | CYP11B2 (0.66) | SLC22A12RPS6KA3CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL14225083 | 0.75 | CYP11B1 (0.58) | SLC22A12RPS6KA3CYP11B1CYP11B2 | |
| SCHEMBL30200169 | 0.75 | PDE2A (0.39) | SLC22A12CYP11B1CYP11B2EGLN2 | |
| SCHEMBL30199155 | 0.75 | PDE2A (0.39) | SLC22A12CYP11B1CYP11B2EGLN2 | |
| SCHEMBL29098047 | 0.75 | PDE2A (0.39) | SLC22A12CYP11B1CYP11B2EGLN2 | |
| SCHEMBL29098018 | 0.75 | PDE2A (0.39) | SLC22A12CYP11B1CYP11B2EGLN2 | |
| SCHEMBL29098016 | 0.75 | PDE2A (0.39) | SLC22A12CYP11B1CYP11B2EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| CN-102712589-A | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | SLC22A12 2415/4885RPS6KA3 1352/4885CYP11B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.